@article {Nissen2021.03.15.21253572, author = {Sara Konstantin Nissen and Kristine Farmen and Mikkel Carstensen and Claudia Schulte and David Goldeck and Kathrin Brockmann and Marina Romero-Ramos}, title = {Changes in CD163+, CD11b+, and CCR2+ peripheral monocytes relate to Parkinson{\textquoteright}s disease and cognition}, elocation-id = {2021.03.15.21253572}, year = {2021}, doi = {10.1101/2021.03.15.21253572}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Alpha-synuclein pathology is associated with immune activation and neurodegeneration in Parkinson{\textquoteright}s disease. The immune activation involves not only microglia but also peripheral immune cells, such as mononuclear phagocytes found in blood and infiltrated in the brain. Understanding peripheral immune involvement is essential for developing immunomodulatory treatment. Therefore, we aimed to study circulating mononuclear phagocytes in early- and late-stage Parkinson{\textquoteright}s disease, defined by disease duration of less or more than five years, respectively, and analyze their association with clinical phenotypes. We performed a cross-sectional multi-color flow cytometry study on 78 sex-balanced individuals with sporadic Parkinson{\textquoteright}s disease, 28 controls, and longitudinal samples from seven patients and one control. Cell frequencies and surface marker expressions on natural killer cells, monocyte subtypes, and dendritic cells were compared between groups and correlated with standardized clinical scores. We found elevated frequencies and surface levels of migration-(CCR2, CD11b) and phagocytic-(CD163) markers, particularly on classical and intermediate monocytes in early Parkinson{\textquoteright}s disease. HLA-DR expression was increased in advanced stages of the disease, whereas TLR4 expression was decreased in women with Parkinson{\textquoteright}s Disease. The disease-associated immune changes on CCR2 and CD11b correlated with worse cognition. Increased TLR2 expression was related to worse motor symptoms. In conclusion, our data highlights the TLR2 relevance in the symptomatic motor presentation of the disease and a role for peripheral CD163+ and migration-competent monocytes in Parkinson{\textquoteright}s disease cognitive defects. Our study suggests that the peripheral immune system is dynamically altered in Parkinson{\textquoteright}s disease stages and directly related to both symptoms and the sex bias of the disease.HighlightsTLR2 expression increased in patients with worse motor symptoms.Increased CD163 and HLA-DR monocytic expression in patients with long PD duration.Sexual-dimorphism for CCR2, CD11b, and TLR4 expression on PD monocytes.CCR2 and CD11b expression are associated with cognitive impairment in PD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding support for the research covered by this article was provided by the Michael J. Fox Foundation (MRR), the Bjarne Saxhof Fund administered through the Danish Parkinson{\textquoteright}s Foundation (MRR) and the Danish Council for Independent Research (MRR).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of the University of Tuebingen (Germany) committee (480/2015BO2).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data supporting the conclusions are included within the article and its additional file.}, URL = {https://www.medrxiv.org/content/early/2021/12/15/2021.03.15.21253572}, eprint = {https://www.medrxiv.org/content/early/2021/12/15/2021.03.15.21253572.full.pdf}, journal = {medRxiv} }